Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.74M$3.74Mderived−27.4% vs Q4 2020 Net Income-$25.56M-$25.56MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$24,838,000N/M Operating Cash Flowderived-$20,710,000N/M Free Cash Flowderived-$21,224,000N/M Margins · derivedOperating margin-664.7%−413.7 pt vs Q4 2020
Net margin-684.1%−444.8 pt vs Q4 2020
ended Dec 31, 2021 · filed Mar 1, 2022 · 60 d after period end